Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:48 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TBL 12 Clear all
Completed Phase 4 Interventional Results available

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

NCT01218100
View directory record Official record
Conditions
Stage 2 Diastolic Hypertension
Interventions
nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 64 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
89
States / cities
Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Nov 3, 2026, 5:48 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

NCT02153645
View directory record Official record
Conditions
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Interventions
240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Nov 3, 2026, 5:48 PM EST
Withdrawn Phase 4 Interventional

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

NCT00711204
View directory record Official record
Conditions
Severe Alzheimer's Disease
Interventions
Donepezil Hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 2 Interventional

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

NCT01204762
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
pegIFN, pegIFNα-2a, PegIFN lambda, Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Anaheim, California • Garden Grove, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Nov 3, 2026, 5:48 PM EST
Not listed Phase 2 Interventional

Effect of Hemp-CBD on Patients With CIPN

NCT04398446
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer, Ovarian Cancer, Uterine Cancer, Pancreatic Cancer
Interventions
Hemp-based CBD, Placebo oral tablet
Drug · Other
Lead sponsor
Main Line Health
Other
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Nov 3, 2026, 5:48 PM EST
Terminated Phase 2 Interventional Results available

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857
View directory record Official record
Conditions
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
Interventions
Sorafenib (Nexavar)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Nov 3, 2026, 5:48 PM EST
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960
View directory record Official record
Conditions
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions
cabozantinib, atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 3 Interventional Results available

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
4,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 5:48 PM EST
Completed No phase listed Observational Results available

Remote Assessment of Physical Function

NCT04339959
View directory record Official record
Conditions
Cancer Survivors
Interventions
Remote Assessment of Physical Function with Direct Observation, Remote Assessment of Physical Function
Other
Lead sponsor
University of New Mexico
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Nov 3, 2026, 5:48 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666
View directory record Official record
Conditions
Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions
Aficamten, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
12 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 3, 2026, 5:48 PM EST
Recruiting Phase 2 Interventional

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07643766
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ENV-294, Placebo
Drug · Other
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 3 Interventional Results available

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

NCT03678753
View directory record Official record
Conditions
Primary Generalized Epilepsy
Interventions
Cenobamate, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
12 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Tuscon, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Colchicine With an Oral Contraceptive

NCT01040845
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Norethindrone/Ethinyl Estradiol, Colchicine, Placebo (for Colchicine)
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Nov 3, 2026, 5:48 PM EST
Terminated Not applicable Interventional Results available

Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases

NCT02715856
View directory record Official record
Conditions
Bone Metastases, Cancer Survivor, Metastatic Malignant Neoplasm in the Bone
Interventions
Monitoring Device, Physical Activity Measurement, Quality-of-Life Assessment, Questionnaire Administration, Standard Follow-Up Care, Survey Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antenatal Micronutrient Supplementation and Infant Survival

NCT00860470
View directory record Official record
Conditions
Infant Mortality, Preterm Birth, Low Birth Weight, Neonatal Mortality, Perinatal Mortality
Interventions
Iron (27 mg) - folic acid (600 ug), Multiple micronutrient
Dietary Supplement
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
44,567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Nov 3, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

R5 Integrase Study in HIV-1 Naive Patients

NCT01204905
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Maraviroc in combination
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Nov 3, 2026, 5:48 PM EST
Terminated Phase 2 Interventional

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

NCT03113994
View directory record Official record
Conditions
Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome
Interventions
Rosuvastatin Calcium, Placebo Oral Tablet, Coenzyme Q10, Calcium Carbonate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Dr. B. Catharine. Craven
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

NCT02378961
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

NCT03682705
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Elsubrutinib, Upadacitinib, Placebo for elsubrutinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
78
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Nov 3, 2026, 5:48 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers

NCT01633437
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CX157, Placebo
Drug · Other
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Nov 3, 2026, 5:48 PM EST
Recruiting Phase 3 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo-Matching Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 5:48 PM EST
Terminated Phase 2 Interventional Results available

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

NCT03780543
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 71 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Nov 3, 2026, 5:48 PM EST
Active, not recruiting Phase 2 Interventional

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

NCT05743244
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 3, 2026, 5:48 PM EST